keyword
MENU ▼
Read by QxMD icon Read
search

cancer subtype

keyword
https://www.readbyqxmd.com/read/29913459/clinical-characteristics-and-prognosis-of-pregnancy-associated-breast-cancer-poor-survival-of-luminal-b-subtype
#1
Soo Youn Bae, Seung Pil Jung, Eun Sung Jung, Sung Min Park, Se Kyung Lee, Jong Han Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam
BACKGROUND: Pregnancy-associated breast cancer (PABC) is rare and is generally defined as breast cancer diagnosed during pregnancy or within 1 year of delivery. The average ages of marriage and childbearing are increasing, and PABC is expected to also increase. This study is intended to increase understanding of the characteristics of PABC. METHODS: A database of 2,810 patients with breast cancer diagnosed when they were less than 40 years of age was reviewed. The clinicopathological factors and survival of PABC (40 patients) were compared to those of patients with young breast cancer (YBC, non-pregnant or over 12 months after delivery; 2,770 patients)...
June 18, 2018: Oncology
https://www.readbyqxmd.com/read/29912993/plasmatic-membrane-toll-like-receptor-expressions-in-human-astrocytomas
#2
Isabele Fattori Moretti, Daiane Gil Franco, Thais Fernanda de Almeida Galatro, Sueli Mieko Oba-Shinjo, Suely Kazue Nagahashi Marie
Toll-like receptors (TLRs) are the first to identify disturbances in the immune system, recognizing pathogens such as bacteria, fungi, and viruses. Since the inflammation process plays an important role in several diseases, TLRs have been considered potential therapeutic targets, including treatment for cancer. However, TLRs' role in cancer remains ambiguous. This study aims to analyze the expression levels of plasmatic cell membrane TLRs (TLR1, TLR2, TLR4, TLR5, and TLR6) in human astrocytomas the most prevalent tumors of CNS different grades (II-IV)...
2018: PloS One
https://www.readbyqxmd.com/read/29912901/germline-mutations-and-somatic-inactivation-of-trim28-in-wilms-tumour
#3
Benjamin J Halliday, Ryuji Fukuzawa, David M Markie, Richard G Grundy, Jackie L Ludgate, Michael A Black, Jane E Skeen, Robert J Weeks, Daniel R Catchpoole, Aedan G K Roberts, Anthony E Reeve, Ian M Morison
Wilms tumour is a childhood tumour that arises as a consequence of somatic and rare germline mutations, the characterisation of which has refined our understanding of nephrogenesis and carcinogenesis. Here we report that germline loss of function mutations in TRIM28 predispose children to Wilms tumour. Loss of function of this transcriptional co-repressor, which has a role in nephrogenesis, has not previously been associated with cancer. Inactivation of TRIM28, either germline or somatic, occurred through inactivating mutations, loss of heterozygosity or epigenetic silencing...
June 2018: PLoS Genetics
https://www.readbyqxmd.com/read/29912871/ar-negative-triple-negative-or-quadruple-negative-breast-cancers-in-african-american-women-have-an-enriched-basal-and-immune-signature
#4
Melissa Davis, Shweta Tripathi, Raymond Hughley, Qinghua He, Sejong Bae, Balasubramanyam Karanam, Rachel Martini, Lisa Newman, Windy Colomb, William Grizzle, Clayton Yates
There is increasing evidence that Androgen Receptor (AR) expression has prognostic usefulness in Triple negative breast cancer (TNBC), where tumors that lack AR expression are considered "Quadruple negative" Breast Cancers ("QNBC"). However, a comprehensive analysis of AR expression within all breast cancer subtypes or stratified by race has not been reported. We assessed AR mRNA expression in 925 tumors from The Cancer Genome Atlas (TCGA), and 136 tumors in 2 confirmation sets. AR protein expression was determined by immunohistochemistry in 197 tumors from a multi-institutional cohort, for a total of 1258 patients analyzed...
2018: PloS One
https://www.readbyqxmd.com/read/29912582/biomarkers-of-aggressiveness-in-genitourinary-tumors-with-emphasis-on-kidney-bladder-and-prostate-cancer
#5
Alessia Cimadamore, Silvia Gasparrini, Matteo Santoni, Liang Cheng, Antonio Lopez-Beltran, Nicola Battelli, Francesco Massari, Francesca Giunchi, Michelangelo Fiorentino, Marina Scarpelli, Rodolfo Montironi
Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses...
June 18, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/29911527/basal-cell-carcinoma-of-the-buttock
#6
REVIEW
Philip R Cohen
Basal cell carcinoma of the buttock is rare, and only 28 patients have been described. An extensive literature search was performed on basal cell carcinoma and buttock using the PubMed database. The literature was evaluated, and the characteristics of individuals with basal cell carcinoma of the buttock were summarized. The calculated prevalence of basal cell carcinoma of the buttock was 0.35%. The majority of patients had no obvious basal cell carcinoma-associated risk factors. Carcinomas were observed 1.2 times more often in women than in men, and more often on the right buttock...
2018: Skinmed
https://www.readbyqxmd.com/read/29911489/interleukin-13-receptor-alpha-2-expression-in-tumor-cells-is-associated-with-reduced-disease-free-survival-in-patients-with-luminal-subtype-invasive-breast-cancer
#7
Hee Jung Kwon, Jung Eun Choi, Young Kyung Bae
Interleukin-13 receptor alpha 2 is one of the subunits of transmembrane receptor for interleukin-13. The aim of this study was to investigate the prognostic value of interleukin-13 receptor alpha 2 expression in invasive breast cancer. Interleukin-13 receptor alpha 2 expressions were assessed by immunohistochemistry in tissue microarrays of 1283 invasive breast cancer samples, and associations between these expressions and clinicopathological variables and clinical outcomes were investigated. Interleukin-13 receptor alpha 2 expression was observed in 138 (10...
June 2018: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29911111/understanding-patterns-of-brain-metastasis-in-breast-cancer-and-designing-rational-therapeutic-strategies
#8
REVIEW
Evelyn M Brosnan, Carey K Anders
One of the most feared sequelae after a diagnosis of advanced breast cancer is development of metastases to the brain as this diagnosis can affect physical function, independence, relationships, quality of life, personality, and ultimately one's sense of self. The propensity to develop breast cancer brain metastases (BCBMs) varies by subtype, occurring in up to one half of those with triple negative breast cancer (TNBC), approximately a third of HER+ breast cancers and 14% in hormone positive disease. Median survival after BCBM diagnosis can be as short as 5 months in TNBC and 10-18 months in the other subtypes...
May 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29911109/prostate-cancer-in-the-era-of-omic-medicine-recognizing-the-importance-of-dna-damage-repair-pathways
#9
REVIEW
Zachary Kornberg, Jonathan Chou, Felix Y Feng, Charles J Ryan
Data from recent high-throughput studies analyzing local and advanced prostate cancer have revealed an incredible amount of biological diversity, which has led to the classification of distinct molecular tumor subtypes. While integrating prostate cancer genomics with clinical medicine is still at its infancy, new approaches to treat prostate cancer are well underway and being studied. With the recognition that DNA damage repair (DDR) mutations play an important role in the pathogenesis of this disease, clinicians can begin to utilize genomic information in complex treatment decisions for prostate cancer patients...
May 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29910679/the-suppression-of-dusp5-expression-correlates-with-paclitaxel-resistance-and-poor-prognosis-in-basal-like-breast-cancer
#10
Tieju Liu, Huizhi Sun, Shiqi Liu, Zhao Yang, Linqi Li, Nan Yao, Siqi Cheng, Xueyi Dong, Xiaohui Liang, Chen Chen, Yi Wang, Xiulan Zhao
Basal-like breast cancer (BLBC) is resistant to endocrinotherapy and targeted therapy and new molecular therapies are needed for BLBC. In this study, we evaluated the role of DUSP1 and DUSP5, negative regulators of mitogen-activated protein kinase pathway, in the aggressiveness of BLBC. MDA-MB-231 cells were given paclitaxel (PTX) treatment and subsequently PTX resistant cell clones were established. Microarray analysis, real-time quantitative reverse transcription PCR (qRT-PCR), and online analysis of large cohorts of breast cancer patients were performed...
2018: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29910657/advances-in-the-systemic-treatment-of-triple-negative-breast-cancer
#11
REVIEW
J M Lebert, R Lester, E Powell, M Seal, J McCarthy
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29910655/clinical-application-and-utility-of-genomic-assays-in-early-stage-breast-cancer-key-lessons-learned-to-date
#12
REVIEW
S K L Chia
Early-stage hormone receptor-positive breast cancer is the most common subtype and stage presenting in countries with organized screening programs. Standard clinical and pathologic factors are routinely used to support prognosis and decisions about adjuvant therapies. Hormone receptor and her2 status are essential for decision-making about the use of adjuvant hormonal and anti-her2 therapies respectively. Genomic assays are now commercially available to aid in either further prognostication or in refining the potential benefit of adjuvant chemotherapy...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29910648/alk-inhibitors-resistance-development-clinical-trials
#13
REVIEW
J M Rothenstein, N Chooback
The treatment of advanced non-small-cell lung cancer (nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of the disease, based on oncogenic drivers, has led to the development of personalized medicine and the ability to deliver molecularly targeted therapies to patients. In the 10 years that have elapsed since the discovery of the ALK gene in a patient with nsclc, several active drugs have moved rapidly from bench to bedside, and multiple others are currently in clinical trials...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29909898/clinicopathological-characteristics-and-outcome-of-31-patients-with-etv6-ntrk3-fusion-gene-confirmed-mammary-analogue-secretory-carcinoma-of-salivary-glands
#14
E Boon, M H Valstar, W T A van der Graaf, E Bloemena, S M Willems, C A Meeuwis, P J Slootweg, L A Smit, M A W Merkx, R P Takes, J H A M Kaanders, P J T A Groenen, U E Flucke, C M L van Herpen
OBJECTIVES: In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma (SC), was defined, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and outcome data of this histological subtype tumor are still sparse, we aimed to describe the clinicopathological course and outcome of a series of translocation positive SC patients. PATIENT AND METHODS: We re-evaluated the pathological diagnosis of a subset of SGCs, diagnosed in 4 of 8 Dutch head and neck centers...
July 2018: Oral Oncology
https://www.readbyqxmd.com/read/29909492/modelling-glioma-invasion-using-3d-bioprinting-and-scaffold-free-3d-culture
#15
Derek M van Pel, Kaori Harada, Dandan Song, Christian C Naus, Wun Chey Sin
Glioma is a highly aggressive form of brain cancer, with some subtypes having 5-year survival rates of less than 5%. Tumour cell invasion into the surrounding parenchyma seems to be the primary driver of these poor outcomes, as most gliomas recur within 2 cm of the original surgically-resected tumour. Many current approaches to the development of anticancer therapy attempt to target genetic weaknesses in a particular cancer, but may not take into account the microenvironment experienced by a tumour and the patient-specific genetic differences in susceptibility to treatment...
June 16, 2018: Journal of Cell Communication and Signaling
https://www.readbyqxmd.com/read/29909259/survival-benefit-of-surgical-removal-of-primary-tumor-in-patients-with-stage-iv-breast-cancer
#16
Hye Jin Kim, Eunyoung Kang, Jee Hyun Kim, Se Hyun Kim, Yu Jung Kim, In Ah Kim, Keun-Yong Eom, Su Min Chae, Kyu Min Kang, Eun Kyu Kim, Sung-Won Kim
BACKGROUND: Several studies have suggested that primary tumor removal improved overall survival for patients with stage IV breast cancer. However, the survival benefit of local treatment remains controversial. The purpose of the present study was to determine whether surgical removal of the primary tumor provides survival benefits to patients with stage IV breast cancer. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 155 patients with an initial diagnosis of stage IV breast cancer at Seoul National University Bundang Hospital from 2003 to 2014...
May 28, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29907769/massive-expression-of-germ-cell-specific-genes-is-a-hallmark-of-cancer-and-a-potential-target-for-novel-treatment-development
#17
Jan Willem Bruggeman, Jan Koster, Paul Lodder, Sjoerd Repping, Geert Hamer
Cancer cells have been found to frequently express genes that are normally restricted to the testis, often referred to as cancer/testis (CT) antigens or genes. Because germ cell-specific antigens are not recognized as "self" by the innate immune system, CT-genes have previously been suggested as ideal candidate targets for cancer therapy. The use of CT-genes in cancer therapy has thus far been unsuccessful, most likely because their identification has relied on gene expression in whole testis, including the testicular somatic cells, precluding the detection of true germ cell-specific genes...
June 15, 2018: Oncogene
https://www.readbyqxmd.com/read/29907695/cancer-cells-copy-migratory-behavior-and-exchange-signaling-networks-via-extracellular-vesicles
#18
Sander C Steenbeek, Thang V Pham, Joep de Ligt, Anoek Zomer, Jaco C Knol, Sander R Piersma, Tim Schelfhorst, Rick Huisjes, Raymond M Schiffelers, Edwin Cuppen, Connie R Jimenez, Jacco van Rheenen
Recent data showed that cancer cells from different tumor subtypes with distinct metastatic potential influence each other's metastatic behavior by exchanging biomolecules through extracellular vesicles (EVs). However, it is debated how small amounts of cargo can mediate this effect, especially in tumors where all cells are from one subtype, and only subtle molecular differences drive metastatic heterogeneity. To study this, we have characterized the content of EVs shed in vivo by two clones of melanoma (B16) tumors with distinct metastatic potential...
June 14, 2018: EMBO Journal
https://www.readbyqxmd.com/read/29907230/a-novel-retinoid-x-receptor-agonist-uab30-inhibits-rhabdomyosarcoma-cells-in-vitro
#19
Adele P Williams, Alicia M Waters, Jerry E Stewart, Venkatram R Atigadda, Elizabeth Mroczek-Musulman, Donald D Muccio, Clinton J Grubbs, Elizabeth A Beierle
BACKGROUND: While patients with early-stage rhabdomyosarcoma (RMS) have seen steady improvement in prognosis over the last 50 y, those with advanced-stage or high-grade disease continue to have a dismal prognosis. Retinoids have been shown to cause growth suppression and terminal differentiation in RMS cells, but the toxicities associated with retinoic acid limit its use. Rexinoids provide an alternative treatment approach to retinoic acid. Rexinoids primarily bind the retinoid X receptor with minimal retinoic acid receptor binding, the entity responsible for many of the toxicities of retinoid therapies...
August 2018: Journal of Surgical Research
https://www.readbyqxmd.com/read/29906688/in-vitro-and-in-vivo-studies-of-gold-i-azolate-phosphane-complexes-for-the-treatment-of-basal-like-breast-cancer
#20
Valentina Gambini, Martina Tilio, Eunice Wairimu Maina, Cristina Andreani, Caterina Bartolacci, Junbiao Wang, Manuela Iezzi, Stefano Ferraro, Anna Teresa Ramadori, Oumarou Camille Simon, Stefania Pucciarelli, Guojun Wu, Q Ping Dou, Cristina Marchini, Rossana Galassi, Augusto Amici
Basal like breast cancer (BLBC) is a very aggressive subtype of breast cancer giving few chances of survival, against which cisplatin based therapy is a compromise among the anticancer activity, the resistance development and the severe side effects. With the aim of finding new anticancer agents alternative to cisplatin, seven gold(I) azolate/phosphane compounds were evaluated in vitro by MTT tests in human MDA-MB-231, human mammary epithelial HMLE cells overexpressing FoxQ1, and murine A17 cells as models of BLBC...
June 2, 2018: European Journal of Medicinal Chemistry
keyword
keyword
30312
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"